Dan Zabrowski

Learn More
SC-49518 (N-[exo-(hexahydro-1H-pyrrolizine-1-yl)methyl]-2-methoxy-4- amino-5-chlorobenzamide HCl), a new benzamide gastrointestinal prokinetic compound, was investigated to determine its ability to stimulate gastrointestinal motility in vivo and whether these actions could be mediated by agonist activity at the putative 5-hydroxytryptamine (5-HT)4 receptor.(More)
Ivenix (Amesbury, MA, USA) has announced the appointment of Stuart A. Randle (left) as CEO. Prior to joining Ivenix, Randle served as president and CEO of GI Dynamics. He has over 20 years of experience in the life sciences industry, serving also as entrepreneur in residence at Advanced Technology Ventures, president and CEO at ACT Medical, and as a(More)
  • 1